Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-25T11:21:49.256Z Has data issue: false hasContentIssue false

31 - Drugs for epilepsy and movement disorders

Published online by Cambridge University Press:  03 May 2010

Lucio Parmeggiani
Affiliation:
Institute of Child Neurology and Psychiatry, University of Pisa, Italy
Renzo Guerrini
Affiliation:
Neurosciences Unit, Institute of Child Health, The Wolfson Centre, London, UK
Brian Meldrum
Affiliation:
Institute of Psychiatry, King's College Hospital, London, UK
Renzo Guerrini
Affiliation:
University of London
Jean Aicardi
Affiliation:
Hôpital Robert-Debré, Paris
Frederick Andermann
Affiliation:
Montreal Neurological Institute & Hospital
Mark Hallett
Affiliation:
National Institutes of Health, Baltimore
Get access

Summary

Introduction

This chapter is intended as an overview of the different antiepileptic drugs (AED) that can also be used to treat movement disorders and of the rationale for their use. There are two main sections: the first reports in alphabetic order AEDs with a well-established use in both fields (epilepsy and movement disorders); the second contains other AEDs that have a less defined use profile in movement disorder treatment, because of their recent introduction or their narrow spectrum of action. The aim is, whenever possible, to highlight the mechanisms of action that can be shared by the drugs in the treatment of both epilepsy and movement disorders.

Acetazolamide

Acetazolamide (AZM) is a sulfonamide that inhibits carbonic anhydrase, an enzyme responsible for conversion of carbon dioxide and water to bicarbonate (Roblin & Clapp, 1950). Its use in epilepsy has a long history but remains limited (Bergstron et al., 1952; Ramsey & De Toledo, 1997). On the contrary, AZM is highly effective in treating episodic ataxias as serendipitously discovered in a patient misdiagnosed with periodic paralysis (Griggs et al., 1978).

Epilepsy

Although several reports have claimed the efficacy of AZM as an AED, most of these studies were performed before the adoption of the International Classification of the Epilepsies (Commission, 1989) and it is therefore difficult to determine clearly what types of epilepsies respond to the drug.

In partial epilepsies, different open studies indicate more than 50% seizure reduction in 25% to 52% of patients, with a minority of them being seizure free.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×